About Interleukin-2 receptor subunit alpha
Interleukin-2 receptor subunit alpha (IL2RA) is a protein
from Homo sapiens identified by UniProt accession
P01589, 272 residues long.
MolForge cross-references it against 0 known binders and
980 disease associations.
Target properties
| Protein name | Interleukin-2 receptor subunit alpha |
|---|
| UniProt accession | P01589 |
|---|
| Gene | IL2RA |
|---|
| Organism | Homo sapiens |
|---|
| Length | 272 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (980)
Diseases linked to this target (Open Targets).
- immunodeficiency due to CD25 deficiency · score 0.76
- type 1 diabetes mellitus · score 0.61
- multiple sclerosis · score 0.58
- diabetes mellitus · score 0.57
- acute graft vs. host disease · score 0.56
- metastatic melanoma · score 0.53
- asthma · score 0.51
- neoplasm · score 0.51
- kidney cancer · score 0.51
- blood protein measurement · score 0.51
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P01589-F1 | alphafold | PREDICTED | 72.52 | — |
Amino-acid sequence (272 residues)
MDSYLLMWGL LTFIMVPGCQ AELCDDDPPE IPHATFKAMA YKEGTMLNCE CKRGFRRIKS GSLYMLCTGN SSHSSWDNQC QCTSSATRNT TKQVTPQPEE QKERKTTEMQ SPMQPVDQAS LPGHCREPPP WENEATERIY HFVVGQMVYY QCVQGYRALH RGPAESVCKM THGKTRWTQP QLICTGEMET SQFPGEEKPQ ASPEGRPESE TSCLVTTTDF QIQTEMAATM ETSIFTTEYQ VAVAGCVFLL ISVLLLSGLT WQRRQRKSRR TI
Explore Interleukin-2 receptor subunit alpha with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets